MIST - Milestone Pharma inks etripamil development deal for PSVT in Greater China

Milestone Pharmaceuticals ([[MIST]] -1.4%) announces an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia ((PSVT)) and additional cardiovascular conditions in Greater China.Under the terms of the agreement, Milestone will receive an upfront cash payment consisting of $15M and a $5M equity investment by RTW Investments.In addition, Milestone is eligible to receive up to $107.5M in milestone payments and royalties on future sales of etripamil in Greater China.Milestone will supply etripamil and delivery devices to Ji Xing with latter responsible for development and commercialization costs.PSVT is a rapid heart rate condition characterized by intermittent episodes of supraventricular tachycardia that start and stop suddenly and without warning.Earlier today, the company announced results from Phase 3 NODE-301 study evaluating etripamil nasal spray in PSVT and Q1 results.

For further details see:

Milestone Pharma inks etripamil development deal for PSVT in Greater China